• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

统一亨廷顿病评定量表:随访

Unified Huntington's disease rating scale: a follow up.

作者信息

Siesling S, van Vugt J P, Zwinderman K A, Kieburtz K, Roos R A

机构信息

Department of Neurology, Leiden University Medical Centre, The Netherlands.

出版信息

Mov Disord. 1998 Nov;13(6):915-9. doi: 10.1002/mds.870130609.

DOI:10.1002/mds.870130609
PMID:9827615
Abstract

An objective assessment of the clinical findings in patients with Huntington's disease (HD) is necessary for an evaluation of the longitudinal progression of the disease features. The Unified Huntington's Disease Rating Scale (UHDRS) is a scale to assess clinical performance and functional capacity. The authors examined the 1-year change in UHDRS scores in 78 patients with HD examined either in Leiden, the Netherlands (24 men, 25 women), or in Rochester, New York, United States (12 men, 17 women). A significant decline was seen in motor function, measured with the total motor scale. The total dystonia score increased significantly; the total chorea score did not. The frequency of behavioral disorders tended to increase. The scores on independence scale, functional assessment, total functional capacity, and symbol digit decreased significantly. No relation was observed between the UHDRS items and the age at onset or duration of illness. Thirteen patients with 2-year follow up showed a clear increase in score on the total motor scale and a decline on the independence scale and in total functional capacity. The UHDRS may also be used as a tool for determining therapeutic intervention. Annual evaluation of the total motor scale in every patient gives a clear description of the motor progression of the disease. The authors suggest performing a total UHDRS evaluation every second year for every HD patient as part of the routine longitudinal evaluation.

摘要

对亨廷顿舞蹈症(HD)患者的临床发现进行客观评估,对于评估疾病特征的纵向进展是必要的。统一亨廷顿舞蹈症评定量表(UHDRS)是一种用于评估临床表现和功能能力的量表。作者检查了78例HD患者的UHDRS评分在1年中的变化,这些患者分别来自荷兰莱顿(24名男性,25名女性)或美国纽约罗切斯特(12名男性,17名女性)。用总运动量表测量发现运动功能有显著下降。肌张力障碍总分显著增加;舞蹈症总分未增加。行为障碍的频率有增加趋势。独立量表、功能评估、总功能能力和符号数字测验的得分显著下降。未观察到UHDRS各项与发病年龄或病程之间的关联。13例接受2年随访的患者显示,总运动量表得分明显增加,独立量表得分和总功能能力下降。UHDRS也可作为确定治疗干预的工具。每年对每位患者的总运动量表进行评估,可清晰描述疾病的运动进展情况。作者建议,作为常规纵向评估的一部分,每隔一年对每位HD患者进行一次完整的UHDRS评估。

相似文献

1
Unified Huntington's disease rating scale: a follow up.统一亨廷顿病评定量表:随访
Mov Disord. 1998 Nov;13(6):915-9. doi: 10.1002/mds.870130609.
2
A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.统一亨廷顿舞蹈病评定量表运动部分的简化版。
Mov Disord. 1997 Mar;12(2):229-34. doi: 10.1002/mds.870120214.
3
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.统一亨廷顿病评定量表:可靠性与一致性。亨廷顿研究小组。
Mov Disord. 1996 Mar;11(2):136-42. doi: 10.1002/mds.870110204.
4
The unified Huntington's Disease Rating Scale for advanced patients: validation and follow-up study.统一的亨廷顿舞蹈病晚期患者评定量表:验证和随访研究。
Mov Disord. 2013 Dec;28(14):1995-2001. doi: 10.1002/mds.25678. Epub 2013 Oct 9.
5
Electrophysiological deterioration over time in patients with Huntington's disease.亨廷顿舞蹈症患者随时间推移的电生理恶化。
Mov Disord. 2006 Sep;21(9):1350-4. doi: 10.1002/mds.20966.
6
Assessment of adaptive functioning in Huntington's disease.亨廷顿舞蹈症的适应性功能评估。
Mov Disord. 1993 Apr;8(2):183-90. doi: 10.1002/mds.870080212.
7
Functional decline in Huntington's disease.亨廷顿舞蹈症中的功能衰退
Mov Disord. 1995 Mar;10(2):211-4. doi: 10.1002/mds.870100213.
8
Complex movement behaviour and progression of Huntington's disease.亨廷顿舞蹈症的复杂运动行为与病情进展
Neurosci Lett. 2007 Apr 18;416(3):272-4. doi: 10.1016/j.neulet.2007.02.027. Epub 2007 Feb 11.
9
Unified Huntington's disease rating scale: clinical practice and a critical approach.统一亨廷顿舞蹈病评定量表:临床实践与批判性方法
Funct Neurol. 2006 Oct-Dec;21(4):217-21.
10
Bradykinesia in Huntington's disease. A prospective, follow-up study.亨廷顿舞蹈症中的运动迟缓。一项前瞻性随访研究。
J Neurol. 2002 Apr;249(4):437-40. doi: 10.1007/s004150200035.

引用本文的文献

1
How to measure the motivations of sports volunteers in Poland? First stage of the study with the Polish adaptation and validation of the VMS-ISE.如何衡量波兰体育志愿者的动机?对VMS-ISE进行波兰语改编和验证的研究第一阶段。
BMC Sports Sci Med Rehabil. 2025 Jul 2;17(1):155. doi: 10.1186/s13102-025-01201-7.
2
The impact of expiratory muscle strength training on voluntary cough effectiveness in Huntington's disease.呼气肌力量训练对亨廷顿病患者自主咳嗽有效性的影响。
Eur J Neurol. 2024 Dec;31(12):e16500. doi: 10.1111/ene.16500. Epub 2024 Sep 30.
3
Protocol for a randomised controlled unblinded feasibility trial of HD-DRUM: a rhythmic movement training application for cognitive and motor symptoms in people with Huntington's disease.
HD-DRUM随机对照非盲法可行性试验方案:一种针对亨廷顿舞蹈症患者认知和运动症状的节律性运动训练应用
BMJ Open. 2024 Jul 31;14(7):e082161. doi: 10.1136/bmjopen-2023-082161.
4
A Practical Guide for Clinical Approach to Patients With Huntington's Disease in Korea.韩国亨廷顿舞蹈病患者临床诊疗实用指南
J Mov Disord. 2024 Apr;17(2):138-149. doi: 10.14802/jmd.24040. Epub 2024 Mar 12.
5
High Levels of Mutant Huntingtin Protein in Tear Fluid From Huntington's Disease Gene Expansion Carriers.亨廷顿舞蹈症基因扩增携带者泪液中突变型亨廷顿蛋白水平较高。
J Mov Disord. 2024 Apr;17(2):181-188. doi: 10.14802/jmd.24014. Epub 2024 Feb 21.
6
Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis.亨廷顿舞蹈症药物研发:一项3期管线分析
Pharmaceuticals (Basel). 2023 Oct 24;16(11):1513. doi: 10.3390/ph16111513.
7
Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis.白细胞介素-6作为亨廷顿舞蹈病进展的标志物:系统评价与荟萃分析
Brain Behav Immun Health. 2023 May 5;30:100635. doi: 10.1016/j.bbih.2023.100635. eCollection 2023 Jul.
8
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.Pepinemab 抗体阻断 SEMA4D 在早期亨廷顿病中的作用:一项随机、安慰剂对照、2 期临床试验。
Nat Med. 2022 Oct;28(10):2183-2193. doi: 10.1038/s41591-022-01919-8. Epub 2022 Aug 8.
9
Huntington's disease and neurovascular structure of retina.亨廷顿病与视网膜神经血管结构。
Neurol Sci. 2022 Oct;43(10):5933-5941. doi: 10.1007/s10072-022-06232-3. Epub 2022 Jun 30.
10
Mutation-related magnetization-transfer, not axon density, drives white matter differences in premanifest Huntington disease: Evidence from in vivo ultra-strong gradient MRI.基因突变相关的磁化传递,而非轴突密度,驱动了无症状亨廷顿病的白质差异:来自活体超强梯度 MRI 的证据。
Hum Brain Mapp. 2022 Aug 1;43(11):3439-3460. doi: 10.1002/hbm.25859. Epub 2022 Apr 9.